Alembic's revenues down 3% as API exports slide
This article was originally published in Scrip
Alembic of India has reported a 3% decline in sales to Rs2.83 billion ($60.9 million) for the quarter ended 30 June, hit by a slide in exports of active pharmaceutical ingredients (APIs). Net profits for the quarter declined to Rs114.8 million compared with Rs122.5 million in the corresponding quarter of the previous fiscal year.
You may also be interested in...
Private equity group Carlyle has acquired 20% of Piramal’s pharma business for close to $500m, with the Indian group expected to use the capital raise to bolster organic and inorganic growth and deleverage the balance sheet.
Fujifilm Toyama seals three-way deal to accelerate the development and global supply of favipiravir, close on the heels of the arrival of a generic version of the antiviral in India under restricted emergency use for the treatment of COVID-19.
Glenmark’s innovation spin-out initiates efforts to raise capital in the US, unfazed by mixed top-line results for its investigational atopic dermatitis treatment. Its parent firm has underscored the value proposition of the oncology franchise and proprietary bispecific antibody technology platform.